Phase 2 N=166 BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Cancer
Primary: Number of Participants With Adverse Events — 3; 4; 36; 50 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer
Bladder Cancer
Primary: Maximum Tolerated Dose (MTD) of Chemophase in Combination With MMC — 800000 Units
Phase 2 N=75 Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Number of Subjects Who Achieved Morphologic Complete Remission — 14; 8; 11 Participants
Phase 2 N=243 Phase 2B Upper Extremity Nerve Block Study
Postoperative Pain
Primary: Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 24 Hours Postsurgery (AUC0-24). — 124.51; 136.17…
Phase 2 N=239 The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
Adult Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in Conners' Adult ADHD Rating Scales-Observer: Screening Version (CAARS-O:SV) 18-item ADHD Symptoms Total Score at Day 56 — 40.71; 41.59; 40.51…
Phase 2 N=50 Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Breast Cancer · Ductal Carcinoma · Invasive Breast Carcinoma
Primary: Phase I: Maximum Tolerated Dose (MTD) / Recommended Phase II Dose (RP2D) — 100 million plaque forming units per mL
Phase 2 N=82 A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants
Respiratory Syncytial Virus Infections
Primary: Number of Subjects With Any Solicited Local Adverse Events (AEs) — 1; 2; 0; 2 Participants
Phase 2 N=119 Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Solid Tumor
Primary: Number of Patients With Drug-related Treatment-emergent Adverse Events (TEAEs) — 3; 1; 1; 11 Participants
Phase 2 N=47 Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
Glioblastoma · Recurrent Adult Brain Neoplasm · Malignant Glioma
Primary: Number of Participants With 6-Month Progression Free Survival (PFS) — 8; 25; 14 Participants
Phase 2 N=275 OK432 (Picibanil) in the Treatment of Lymphatic Malformations
Lymphatic Malformations
Primary: Number of Participants With Clinical Success at 1 to 6 Months Post-Therapy as Assessed by Imaging — 57 Participants
Phase 2 N=121 A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
Nonalcoholic Fatty Liver
Primary: Relative Change in the Percentage of Liver Fat Mass (Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction [MRI-PDFF]) From Baseline to Week 12/End of…
Phase 2 N=41 BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
Marginal Zone Lymphoma · Follicular Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Overall Response Rate (ORR) As Measured By The Investigator — 35; 56.3; 60.0 Percentage of Participants
Phase 2 N=8 MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Inherited Metabolic Disorders (IMD)
Primary: Number of Participants With Engraftment — 6; 2 Participants
Phase 2 N=91 A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Primary: Determination of Maximum Tolerated Dose and / or Recommended Dose and Dosing Regimen of MOR03087 — 16; 16; 16; 16 mg/kg
Phase 2 N=6 S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
DS Stage I Plasma Cell Myeloma · DS Stage II Plasma Cell Myeloma · DS Stage III Plasma Cell Myeloma
Primary: Phase I: Maximum Tolerated Dose (MTD) of Elotuzumab in Combination With Bortezomib, Lenalidomide and Dexamethasone — 10 mg/kg (Phase II dosing for elotuzumab)